ArticleAlzheimer's & dementia (New York, N. Y.)2022

A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia.

Lucy Vivash et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.